AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00385736 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: Prefilled syringe, 40 mg (loading dose then every other week dosing). 160 mg at Week 0, 80 mg at Week 2, and 40 mg every other week starting at Week 4.
Study NCT00385736 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo for 40 mg syringe. Matching placebo for loading dose and every other week dosing. Subjects received placebo at Weeks 0, 2, 4, and 6, followed by 160 mg adalimumab at Week 8, 80 mg adalimumab at Week 10, and 40 mg adalimumab eow thereafter (prior to Amendment 3) or 40 mg adalimumab eow starting at Week 8 (after Amendment 3).
Study NCT03306238 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open approach to port insertion
Description: This involves the peritoneum being cut down, followed by the insertion of a blunt trocar under direct visualisation, gas insufflation, and insertion of the laparoscope
Study NCT03306238 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Closed approach to port insertion
Description: This involves the insertion of a Veress needle (a needle equipped with a spring-loaded obturator) into the peritoneal cavity, followed by gas insufflation (act of blowing) and insertion of a trocar (a sharp, pointed instrument with a cannula used to enter the body cavity).
Study NCT00048139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 250mg/m2 iv on day 1 of each 3 week cycle
Study NCT00048139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine [Xeloda]
Description: 1000mg/m2 po bid on days 1-15 of each 3 week cycle
Study NCT03595722 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Intensity Focused Ultrasound
Description: High intensity focused ultrasound to rectal/pelvic cancer
Study NCT03621215 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tart cherry juice
Description: 30 mL tart cherry juice concentrate (CherryActive, UK), diluted with water to 250 mL. This is consumed daily by participants, with breakfast, for 12 months.
Study NCT03621215 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Fruit-flavoured placebo drink
Description: Consumed daily by participants, with breakfast, for 12 months.
Study NCT03377998 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: skin biopsy
Description: Skin biopsy for measuring tissue levels of the Erythroid differentiation regulator 1 (Erdr1) cytokine will be taken from the lesional skin of patients of vitiligo and from normal skin of healthy controls.
Study NCT03189927 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BD-Covered esophageal stent
Description: a biodegradable covered stent is implanted to achieve a long-term relieve of dysphagia in refractory benign esophageal strictures
Study NCT02477033 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Butyricicoccus pullicaecorum 25-3T
Study NCT02477033 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Study NCT02144818 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ovitrel
Description: Triggering of ovulation with Ovitrel
Study NCT02144818 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Decapeptyl
Description: Triggering with GnRH agonist
Study NCT00908141 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: Given subcutaneously on varying schedule
Study NCT01188590 — intervention group
Intervention type: DEVICE
Intervention: TOSCA 500 monitor
Description: transcutaneous ear lobe probe that monitors pulse rate, oxygen saturation and carbon dioxide levels
Study NCT02349854 — intervention group
Intervention type: PROCEDURE
Intervention: Biopsy
Description: 1 scalp biopsy will be done at the site of central sensitization testing, according to standard of care practices. First, the site will be anesthetized and within this area, 2 immediately adjacent (ie contiguous) punch biopsies will be taken-2mm \& 3mm. Both will be closed simultaneously using either (i) non fast-absorbing gut sutures, requiring a 10-14 day follow-up visit for suture removal; (ii) fast absorbing gut sutures that will not require a subsequent suture removal visit, or (iii) gel foam without stitches that also does not require a suture removal visit. Wound care instruction will be discussed with patient. The patient will be instructed to apply petroleum jelly at least 3 times per day to the biopsy site, reflecting standard of care clinical care at BMC.
Study NCT03344120 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Administration of USSQ Symptoms questionnaire after stent positioning
Description: Administration of USSQ Symptoms questionnaire to patients with two different type of stents after ureteroscopy
Study NCT01894009 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Foot manipulation
Description: The subtalar joint was treated with gapping thrust with patient lying on the contra-lateral side. Mobilisation of the distal tibia-fibula was performed with the patient squatting and was repeated 10 times. Home training programs in order to maintain the mobility in the joints were given.
Study NCT01894009 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham foot manipulation
Description: Sham manipulation included downsizing (a massage technique) the section underneath the heel from back forwards with four grips and palpation of the five metatarsal bones. Sham manipulations were repeated 10 times. This group was also recommended home exercises in the mornings.
Study NCT03119896 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Navigator Tool Intervention
Description: The intervention consists of two parts; a training session on self-management of chronic conditions for the healthcare professionals, and a paper-based tool for the patients. Both parts aim to inform and prepare the two parties as to what self-management entails in order to facilitate a constrictive consultation.
Study NCT04111952 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CO2 laser
Description: A single session of CO2 vaginal laser treatment
Study NCT04111952 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham laser
Description: A single session of sham laser treatment.
Study NCT03257176 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stepping Stones and Creating Futures
Description: 21 session intervention, comprising of 10 Stepping Stones sessions focused on gender, relationships and communication. 11 Creating Futures sessions focused on livelihoods.
Study NCT04375475 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bright Changyou probiotic flavored yogurt
Description: Oral consumption of Bright Changyou probiotic flavored yogurt 100 g at a time and twice per day for 28 days. The experimental product has similar package and taste as the comparators.
Study NCT04375475 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Bright Changyou lactobacillus flavored yogurt
Description: Oral consumption of Bright Changyou lactobacillus flavored yogurt 100 g at a time and twice per day for 28 days.
Study NCT04375475 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Bright flavored yogurt
Description: Oral consumption of Bright flavored yogurt 100 g at a time and twice per day for 28 days.
Study NCT02385188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod
Description: topical 5% imiquimod cream 3 times a week for 16 weeks.
Study NCT02385188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paracetamol
Study NCT02385188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine in Vaseline ointment
Study NCT01011023 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non application of nasogastric tube in the experimental group
Description: Avoid the 5 post operative application of nasogastric tube in the experimental group vs the control group with the usual nasogastric tube
Study NCT01011023 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non application of nasogastric tube in the experimental group
Description: Avoid the 5 post operative application of nasogastric tube in the experimental group vs the control group with the usual nasogastric tube
Study NCT00723203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: panobinostat
Description: 40 mg Monday, Wednesday and Friday of every week in a 28 day cycle
Study NCT00723203 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: gene expression analysis
Description: Day 1 and day 28 samples
Study NCT00723203 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: reverse transcriptase-polymerase chain reaction
Description: Day 1 and day 28 samples
Study NCT00723203 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Day 1 and day 28 samples
Study NCT00095680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCIO-469
Description: two 30-mg capsules three times daily
Study NCT00095680 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SCIO-469 and bortezomib
Description: The addition of bortezomib (treatment regimen or bolus) to monotherapy of SCIO-469 or bortezomib combination with SCIO-469 will be dependent upon clinical response or disease progression during the study
Study NCT03901118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chiauranib
Description: in the phase of pilot trial, 25mg orally once daily; in the formal phase, 50mg orally once daily
Study NCT03901118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: 50mg orally once daily for 21 days, 7 days off, every 28 days for a cycle, 6 cycles at most
Study NCT03901118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: 60mg/m2, i.v infusion on day 1, 8 and 15, every 21 days for a cycle, 6 cycles at most
Study NCT03104231 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: three-dimensional (3D) movie
Description: Brief VR-3D will be shown using the oculus glasses and a smartphone. Then, patients will be asked several questions from the prepared questionnaire.
Study NCT03175991 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ultrasonography
Description: A morphologic evaluation will be performed according to International Ovarian Tumor Analysis Group recommendations for the following parameters:~Bilaterality , wall thickness, septations , papillary projections, solid areas, and echogenicity. The presence of ascites also will be recorded. Pattern recognition analysis will be used for ovarian masses highly suggestive of some diseases , then color Doppler will be activated to identify vascular color signals within the lesion.
Study NCT00525694 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Glucose tolerance test
Description: 10 ounces glucose tolerance test solution
Study NCT00525694 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: glucose tolerance test solution
Description: 75 grams glucose load
Study NCT00525694 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Diet Coke
Description: 10 ounces of Diet Coke
Study NCT00525694 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Coke Zero
Description: 10 ounces of Coke Zero
Study NCT01222247 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betamethasone
Description: The active study drug, betamethasone. 3 mg per ml betamethasone sodium phosphate 3 mg per milliliter betamethasone acetate The first dose of study drug medication will be administered at randomization as 2 ml injection; the next dose of 2 ml will be administered 24 hours later.
Study NCT01222247 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Similar course of identical appearing placebo: 2 mL IM injections, 24 hours apart.
Study NCT03356860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80mg/m2 IV weekly from week 1 to week12
Study NCT03356860 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 80mg/m2 IV weekly from week 1 to week12
Study NCT03356860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: 90 mg/m2 IV Q 2 weeks from week 14 to week 20
Study NCT03356860 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: 90 mg/m2 IV Q 2 weeks from week 14 to week 20
Study NCT03356860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 600 mg/m2 IV Q 2 weeks from week 14 to week 20
Study NCT03356860 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 600 mg/m2 IV Q 2 weeks from week 14 to week 20
Study NCT03356860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab 1500 mg IV at week 14 and 18
Study NCT03822624 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Probiotic mixture with three bacterial strains with maltodextrin as a carrier.
Study NCT03822624 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator with maltodextrin as a carrier.
Study NCT01839825 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: QuietCare
Study NCT04391075 — intervention group
Intervention type: PROCEDURE
Intervention: Pudendal nerve block
Description: Pudendal nerve block provided during last fase of delivery
Study NCT02451280 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Unilateral Hybrid Intervention
Description: For the unilateral RT training, participants will practice with their affected arms following a unilateral training protocol of BMT for 45 minutes (Yang, et al., 2012). For the UAT training, participants will receive training of the affected UL in functional tasks with behavioral shaping for 45 minutes (Lin, Wu, et al., 2009).
Study NCT02451280 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral Hybrid Intervention
Description: For the bilateral RT training, patients will focus on training involving both arms using the BMT robot for 45 minutes. During the 45 minutes BAT training, participants will receive training in tasks focusing on bilateral symmetric or alternating movements of both ULs.
Study NCT02451280 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robot-Assisted Training
Description: The RT intervention will be matched in duration and intensity with the hybrid interventions. Participants in the RT group will practice on the BMT with bilateral protocols for 90 minutes. The tasks will be tailored according to the level
Study NCT04055285 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sympathetic Renal Denervation
Description: Catheter-based sympathetic renal denervation (RDN) using radiofrequency, ultrasound, or perivascular injection of neurotoxic agents such as alcohol has been introduced as a minimally invasive alternative treatment option for patients with resistant hypertension. RDN consists of endovascular catalysis of the kidney sympathetic nerves running in the wall of the renal arteries.
Study NCT04055285 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantable Loop Recorder
Description: Implantable Loop Recorders (ILRs) are small, subcutaneously implanted devices that are able to detect and store atrial fibrillation episodes lasting longer than 2 minutes with high sensitivity (96.1-100%) and good specificity (67-85.4%) for a period of up to three years.
Study NCT04055285 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantable Loop Recorder
Description: Implantable Loop Recorders (ILRs) are small, subcutaneously implanted devices that are able to detect and store atrial fibrillation episodes lasting longer than 2 minutes with high sensitivity (96.1-100%) and good specificity (67-85.4%) for a period of up to three years.
Study NCT00877851 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer-based Program
Description: The intervention group will receive an initial training session which will include a demonstration of the layout and main features of the computer-based program and some instructions on how to navigate around the different sections of the program. As a minimum level of use, participants will be asked to use the self-monitoring and goal setting aspects of the computer-based program on at least a weekly basis.
Study NCT01861782 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dead Sea Solar and Water Treatment
Study NCT01861782 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sulfur Pool & Medicinal Mud
Study NCT02431533 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PX0612
Description: PX0612 is a probiotic contained in a veggie capsule.
Study NCT02431533 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Di-Calcium Phosphate
Description: Patients in the 'placebo' group will receive the placebo capsules. The main ingredient in the placebo capsule is Di-Calcium Phosphate
Study NCT01400893 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SCD
Description: The selective cytopheretic device (SCD) is comprised of tubing, connectors and a hemofilter cartridge. The device is connected in series to a commercially available Continuous Renal Replacement Therapy (CRRT) device. Blood from the CRRT circuit is diverted after the CRRT hemofilter through to the extra capillary space (ECS) of the SCD. Blood circulates through this space and is returned to the patient via the venous return line of the CRRT circuit. Regional citrate anticoagulation is used for the entire CRRT and SCD blood circuits.
Study NCT02242461 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rhodiola placebo capsules
Description: Corn starch
Study NCT02242461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rhodiola Crenulata
Description: Rhodiola Crenulata
Study NCT05498311 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intraoperative Radiotherapy (IORT)
Description: The Intrabeam Photon Radiosurgery System will deliver 20 Gy in the act of breast surgery
Study NCT05498311 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Breast conservative surgery
Description: Breast conservative surgery with the aim of resecting breast tumour and with or without oncoplastic surgery
Study NCT05498311 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Hypofractionated Radiotherapy (EBRT)
Description: A External Beam Hypofractionated Radiotherapy will be administered after surgery. y. The dose per fraction will be 2.67 Gy per session. EBRT will be performed daily from Monday to Friday for fifteen fractions.
Study NCT03956576 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: [Pyr]apelin-13
Description: Peptide \[Pyr\]apelin-13 infusion
Study NCT02031744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib [Tarceva]
Description: 150 mg oral administration once daily
Study NCT02031744 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: erlotinib [Tarceva]
Description: 150 mg oral administration once daily
Study NCT02031744 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 15 mg/kg intravenous administration every 3 weeks
Study NCT02031744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onartuzumab [MetMAb]
Description: 15 mg/kg intravenous administration every 3 weeks
Study NCT02490384 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physical exam indicated cerclage
Description: Cervical cerclage
Study NCT03888365 — intervention group
Intervention type: DRUG
Intervention: Treprostinil
Description: Treprostinil treatment will be at the discretion of the participant's physician, and determined on an individual basis.
Study NCT03888365 — intervention group
Intervention type: DRUG
Intervention: Non-Treprostinil PAH Medications
Description: Non-treprostinil treatment will be at the discretion of the participant's physician, and determined on an individual basis.
Study NCT03083743 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant human Apo-2 ligand for Injection
Description: 150μg/kg/d IV (in the vein), on day 1 to 7 of each 21 day cycle
Study NCT03083743 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 150μg/kg/d IV (in the vein), on day 1 to 7 of each 21 day cycle
Study NCT06160921 — intervention group
Intervention type: OTHER
Intervention: Standard therapy
Description: Individualized blood pressure reduction program
Study NCT00935792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alemtuzumab
Description: Given subcutaneously
Study NCT00935792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: Given orally
Study NCT02956967 — intervention group
Intervention type: OTHER
Intervention: Overall satisfaction questionnaires of home use of Nivestim
Study NCT02556723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreal injections of ziv-aflibercept
Description: All subjects will receive intravitreal injections of ziv-aflibercept under sterile conditions at baseline, 4 weeks, 8 weeks, 12 weeks, 16 weeks, and 20 weeks. No topical or systemic antibiotics will be prescribed (pre- injection or postinjection).
Study NCT03585374 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Methoxyflurane and Penthrox inhaler
Description: 3ml of methoxyflurane vaporized through an inhaler (Penthrox). Inhalation, by regular breathing, last about 25 minutes.